 |
| Partly through its involvement with major investor Johnson & Johnson, Mauna Kea Technologies is increasingly focused on applications of its Cellvizio platform in lung cancer diagnostics. A new centre of excellence in Nancy, France, should be a sign of things to come, with plans to establish similar locations in several countries as bronchoscopy screenings for lung cancer detection proliferate in Europe and elsewhere. Image: Auris Health. |
| © 2024 SPIE Europe |
|
